Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket

Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket

10.1093/nar/gky1314

Saved in:

Bibliographic Details
Main Authors:	Pradhan, M.R., Siau, J.W., Kannan, S., Nguyen, M.N., Ouaray, Z., Kwoh, C.K., Lane, D.P., Ghadessy, F., Verma, C.S.
Other Authors:	BIOLOGICAL SCIENCES
Format:	Article
Published:	Oxford University Press 2021
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/212481
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore

Similar Items

Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket
by: Siau, Jia Wei, et al.
Published: (2019)

Conformational landscape of the epidermal growth factor receptor kinase reveals a mutant specific allosteric pocket
by: Kannan, S., et al.
Published: (2022)

Conformational landscape of the epidermal growth factor receptor kinase reveals a mutant specific allosteric pocket
by: Kannan, Srinivasaraghavan, et al.
Published: (2018)

Modulation of p53 binding to MDM2: Computational studies reveal important roles of Tyr100
by: Dastidar, S.G., et al.
Published: (2014)

Long range recognition and selection in IDPs: The interactions of the C-terminus of p53
by: Kannan, S, et al.
Published: (2020)

Structural analysis of protein tyrosine phosphatase 1B reveals potentially druggable allosteric binding sites
by: Kumar, Ammu Prasanna, et al.
Published: (2020)

P53: Updates on mechanisms, biology and therapy (I)
by: Lane, D.P., et al.
Published: (2021)

The dual interactions of p53 with MDM2 and p300: Implications for the design of MDM2 inhibitors
by: Kannan, S., et al.
Published: (2021)

Mapping the structural and dynamical features of multiple p53 DNA binding domains: Insights into loop 1 intrinsic dynamics
by: Lukman, S., et al.
Published: (2014)

Why is F19Ap53 unable to bind MDM2? Simulations suggest crack propagation modulates binding
by: Dastidar, S.G., et al.
Published: (2014)

Mutant p53 accumulates in cycling and proliferating cells in the normal tissues of p53 R172H mutant mice
by: Goh, A.M, et al.
Published: (2020)

Characterizing the conformational landscape of MDM2-binding p53 peptides using Molecular Dynamics simulations
by: Yadahalli, S, et al.
Published: (2020)

Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation
by: Kong, Li Ren, et al.
Published: (2020)

Druggability of human disease genes
by: Sakharkar, M.K., et al.
Published: (2011)

Functional characterization of p53 pathway components in the ancient metazoan Trichoplax adhaerens
by: Siau, J.W, et al.
Published: (2020)

Cancer-derived p53 mutants suppress p53-target gene expression - Potential mechanism for gain of function of mutant p53
by: Vikhanskaya, F., et al.
Published: (2014)

Understanding p53 functions through p53 antibodies
by: Sabapathy, K., et al.
Published: (2021)

Design and synthesis of cyclotides as druggable biologics.
by: Wong, Clarence Tsun Ting.
Published: (2013)

P53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients
by: Bourdon, J.-C, et al.
Published: (2020)

In vitro selection of mutant HDM2 resistant to nutlin inhibition
by: Wei, Siau Jia., et al.
Published: (2014)

The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage
by: Xue, Y, et al.
Published: (2020)

Adaptor regulation of LFA-1 signaling in T lymphocyte migration : potential druggable targets for immunotherapies?
by: Verma, Navin K., et al.
Published: (2015)

Long range recognition and selection in IDPs : the interactions of the C-terminus of p53
by: Kannan, Srinivasaraghavan, et al.
Published: (2018)

Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine
by: Hwang, L.-A., et al.
Published: (2021)

Discovery of druggable biologics from alternanthera paronychiodes
by: Ye, Weijian
Published: (2013)

Druggable Allosteric Sites in β-Propeller Lectins
by: Elena Shanina, et al.
Published: (2022)

Druggable Allosteric Sites in β-Propeller Lectins
by: Shanina E.
Published: (2023)

Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9
by: Chee, J.L.Y., et al.
Published: (2014)

The crystal structure of Escherichia coli spermidine synthase SpeE reveals a unique substrate-binding pocket
by: Zhou, X., et al.
Published: (2014)

Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets
by: Kanojia, D, et al.
Published: (2020)

ACTIVATING MUTANT P53: A DIRECTED EVOLUTION APPROACH
by: GOH LENG PENG
Published: (2012)

c-Abl, an accomplice in mutant p53 gain-of-function?
by: Liu, Di
Published: (2014)

In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition
by: Wei, S.J., et al.
Published: (2014)

Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome
by: Neilsen, P.M, et al.
Published: (2020)

Inhibition of Nutlin-resistant HDM2 mutants by stapled peptides
by: Wei, S.J., et al.
Published: (2014)

Differences in the Binding Affinities of ErbB Family: Heterogeneity in the Prediction of Resistance Mutants
by: Pereira, M., et al.
Published: (2014)

Promyelocytic leukemia protein is required for gain of function by mutant p53
by: Haupt, S., et al.
Published: (2014)

P53: Updates on mechanisms, biology and therapy (II)
by: Verma, C.S.
Published: (2021)

The dual interactions of p53 with MDM2 and p300 : implications for the design of MDM2 inhibitors
by: Kannan, Srinivasaraghavan, et al.
Published: (2020)

Back-Pocket Architecture
by: Chee, Li Lian
Published: (2014)